An Open Label, Single Arm, Multiple Dose Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of LNP023 When Administered in Addition to Standard of Care (SoC) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs LNP-023 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 23 Apr 2018 Planned End Date changed from 18 Dec 2018 to 17 Dec 2018.
- 23 Apr 2018 Planned primary completion date changed from 18 Dec 2018 to 17 Dec 2018.
- 06 Apr 2018 Planned End Date changed from 22 Nov 2018 to 18 Dec 2018.